Literature DB >> 22761295

Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus.

Christine E Mathews1, Eric L Brown, Perla J Martinez, Upasana Bagaria, Moon H Nahm, Robert L Burton, Susan P Fisher-Hoch, Joseph B McCormick, Shaper Mirza.   

Abstract

The goal of the study was to determine baseline protective titers of antibodies to Streptococcus pneumoniae surface protein A (PspA) and capsular polysaccharide in individuals with and individuals without type 2 diabetes mellitus. A total of 561 individuals (131 individuals with diabetes and 491 without) were screened for antibodies to PspA using a standard enzyme-linked immunosorbent assay (ELISA). A subset of participants with antibodies to PspA were retested using a WHO ELISA to determine titers of antibodies to capsular polysaccharide (CPS) (serotypes 4, 6B, 9V, 14, 18C, 19A, 19F, and 23F). Functional activity of antibodies was measured by assessing their ability to enhance complement (C3) deposition on pneumococci and promote killing of opsonized pneumococci. Titers of antibodies to protein antigens (PspA) were significantly lower in individuals with diabetes than controls without diabetes (P = 0.01), and antibodies showed a significantly reduced complement deposition ability (P = 0.02). Both antibody titers and complement deposition were negatively associated with hyperglycemia. Conversely, titers of antibodies to capsular polysaccharides were either comparable between the two groups or were significantly higher in individuals with diabetes, as was observed for CPS 14 (P = 0.05). The plasma specimens from individuals with diabetes also demonstrated a higher opsonophagocytic index against CPS serotype 14. Although we demonstrate comparable protective titers of antibodies to CPS in individuals with and individuals without diabetes, those with diabetes had lower PspA titers and poor opsonic activity strongly associated with hyperglycemia. These results suggest a link between diabetes and impairment of antibody response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761295      PMCID: PMC3428395          DOI: 10.1128/CVI.00268-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea.

Authors:  J S Nam; A R Kim; J C Yoon; Y Byun; S A Kim; K R Kim; S Cho; B L Seong; C W Ahn; J M Lee
Journal:  Diabet Med       Date:  2011-07       Impact factor: 4.359

3.  Diabetes and the risk of infection-related mortality in the U.S.

Authors:  A G Bertoni; S Saydah; F L Brancati
Journal:  Diabetes Care       Date:  2001-06       Impact factor: 19.112

4.  PspC, a pneumococcal surface protein, binds human factor H.

Authors:  S Dave; A Brooks-Walter; M K Pangburn; L S McDaniel
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media.

Authors:  S Rapola; V Jäntti; R Haikala; R Syrjänen; G M Carlone; J S Sampson; D E Briles; J C Paton; A K Takala; T M Kilpi; H Käyhty
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

6.  Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis.

Authors:  T Lahiri; D A Waltz
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

7.  Quantifying the risk of infectious diseases for people with diabetes.

Authors:  Baiju R Shah; Janet E Hux
Journal:  Diabetes Care       Date:  2003-02       Impact factor: 19.112

8.  Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study.

Authors:  Reimar W Thomsen; Heidi H Hundborg; Hans-Henrik Lervang; Søren P Johnsen; Henrik T Sørensen; Henrik C Schønheyder
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

9.  Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG.

Authors:  A Lapolla; D Fedele; M Garbeglio; L Martano; R Tonani; R Seraglia; D Favretto; M A Fedrigo; P Traldi
Journal:  J Am Soc Mass Spectrom       Date:  2000-02       Impact factor: 3.262

10.  The immune response to pneumococcal proteins during experimental human carriage.

Authors:  Tera L McCool; Thomas R Cate; Gregory Moy; Jeffrey N Weiser
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

View more
  7 in total

1.  Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumoniae is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus.

Authors:  Perla J Martinez; Christine Mathews; Jeffrey K Actor; Shen-An Hwang; Eric L Brown; Heather K De Santiago; Susan P Fisher Hoch; Joseph B McCormick; Shaper Mirza
Journal:  Transl Res       Date:  2013-08-05       Impact factor: 7.012

Review 2.  Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes.

Authors:  Santosh Paudel; Preeti P John; Seyedeh Leila Poorbaghi; Tara M Randis; Ritwij Kulkarni
Journal:  J Diabetes Res       Date:  2022-05-17       Impact factor: 4.061

3.  Neuraminidase A-Exposed Galactose Promotes Streptococcus pneumoniae Biofilm Formation during Colonization.

Authors:  Krystle A Blanchette; Anukul T Shenoy; Jeffrey Milner; Ryan P Gilley; Erin McClure; Cecilia A Hinojosa; Nikhil Kumar; Sean C Daugherty; Luke J Tallon; Sandra Ott; Samantha J King; Daniela M Ferreira; Stephen B Gordon; Hervé Tettelin; Carlos J Orihuela
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

4.  Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia.

Authors:  Blanca I Restrepo; Marcel Twahirwa; Mohammad H Rahbar; Larry S Schlesinger
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

5.  Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control.

Authors:  Diana I Gomez; Marcel Twahirwa; Larry S Schlesinger; Blanca I Restrepo
Journal:  Tuberculosis (Edinb)       Date:  2012-11-03       Impact factor: 2.973

Review 6.  The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System.

Authors:  Gholamreza Daryabor; Mohamad Reza Atashzar; Dieter Kabelitz; Seppo Meri; Kurosh Kalantar
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

Review 7.  Immunometabolic bases of type 2 diabetes in the severity of COVID-19.

Authors:  Rebeca Viurcos-Sanabria; Galileo Escobedo
Journal:  World J Diabetes       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.